How Ozempic differs from Wegovy — and why that distinction matters

The big misconception: 'They're the same drug, so they're interchangeable'

This is the most common misunderstanding our prescribers hear, and it's worth clearing up at the start. Yes, Ozempic and Wegovy both deliver semaglutide, a GLP-1 receptor agonist that slows gastric emptying, curbs appetite, and influences blood-sugar regulation. The active molecule is identical. But UK medicines licensing doesn't work on molecules alone; it works on specific products, specific dose ranges, specific indications, and specific trial evidence.

Ozempic was developed and licensed for type 2 diabetes. Its approved doses in the UK sit between 0.5 mg and 2 mg weekly. The clinical programme behind it studied people with diabetes, looking primarily at blood-glucose control and cardiovascular outcomes. Wegovy was developed separately for weight management, studied in people with obesity but without type 2 diabetes as the primary population, and approved at a higher maintenance dose of 2.4 mg weekly, rising to 7.2 mg with the pen approved by the MHRA in April 2026. The NHS medicines page for semaglutide sets out both products clearly and is a useful one-minute reference if you want to check which licence applies to which condition.

Prescribing Ozempic off-licence for weight loss is not standard UK practice. A prescriber taking that route would need to document clinical justification, and most won't, because Wegovy exists specifically for this purpose. So when people ask whether Wegovy is different to Ozempic, the honest answer is: different enough to matter legally, clinically, and practically.

What the dose difference actually means for weight loss

Dose is where the distinction becomes most tangible. Ozempic tops out at 2 mg weekly in its licensed diabetes indication. Wegovy's standard maintenance is 2.4 mg, with both medicines using the same slow titration starting at 0.25 mg to give your digestive system time to adjust. That gap between 2 mg and 2.4 mg sounds small, but the trial data suggest it matters: the STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at 2.4 mg in adults without diabetes.

The newer 7.2 mg Wegovy pen, approved by the MHRA in April 2026 for adults with a BMI of 30 or above, goes further still, trials reported approximately 20.7% average weight loss over 72 weeks at that dose. There is no equivalent diabetes-indication product at that dose level. If someone were taking Ozempic for weight loss, they would be capped well below what the current Wegovy programme can reach. The different strengths exist because weight management and blood-glucose control are different therapeutic goals, studied in different populations, requiring different dose optimisation. For more on how Wegovy's dose ladder works in practice, the guide to Wegovy's different dose levels covers each step.

Side effects across both products share the same GI-led character (nausea, loose stools, constipation, reflux) because the mechanism is the same. Severity tends to peak early in treatment or after a dose increase and ease off within a couple of weeks for most people. Serious effects like pancreatitis are rare but real; the MHRA issued a specific Drug Safety Update on this in January 2026, and anyone on a GLP-1 medicine who develops severe stomach pain spreading to the back should get medical help the same day.

Which one is actually licensed for weight loss in the UK?

Wegovy is the semaglutide product licensed for weight management in the UK. It's approved for adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present, things like high blood pressure, high cholesterol, or obstructive sleep apnoea. Ozempic carries no such licence for weight management. Rybelsus, another semaglutide product (oral tablets at 3, 7, and 14 mg), is also licensed for type 2 diabetes only. For a thorough comparison of how the different semaglutide products relate to each other, the page on the different semaglutide medicines available in the UK lays it out in one place.

Mounjaro (tirzepatide) is the other UK-licensed weight-management injection worth knowing about. It works on two gut-hormone receptors rather than one, and head-to-head trial data from the SURMOUNT-5 study showed greater average weight loss compared with semaglutide 2.4 mg. Whether Wegovy or Mounjaro is the right choice for a given person is a clinical question, one that depends on their health history, current medicines, and what the prescriber judges most appropriate. A free consultation through our treatment page is the starting point if you'd like a prescriber to review your options.

If cost is part of the picture, it's worth reading about what Wegovy actually costs through a private UK pharmacy before making any decisions, prices vary considerably and the headline figure doesn't always tell the whole story.

Ozempic shortages and why people started asking this question

One reason the Ozempic-versus-Wegovy question became so prominent is the supply disruption that ran through 2023 and 2024. Wegovy faced significant shortages in the UK, and some people (or some providers) turned to Ozempic as a substitute. The MHRA and NHS were clear that this was not an appropriate switch; the medicines have different approved populations, different dose structures, and different evidence bases. Prescribing Ozempic for weight loss in that context was, at best, a clinical stretch and, at worst, a supply-chain workaround that left patients on an unlicensed indication.

The supply picture for Wegovy has improved. Novo Nordisk has stated UK availability is more stable, and the newer 7.2 mg pen has launched into a market that can support it. If a provider is still offering Ozempic as a weight-loss treatment, that should prompt questions. The right check is straightforward: look up the pharmacy on the GPhC online register and make sure any treatment you're offered matches its licensed indication. It takes under a minute and tells you whether the pharmacy is legitimately registered in the UK. For a broader picture of the semaglutide landscape, the semaglutide overview covers the licensed products, their indications, and how they compare, and if you're also considering how Wegovy compares to other injectable weight-loss options, the comparison with Saxenda and the full Wegovy guide are both worth a read. Check your eligibility with our prescribers if you're ready to take the next step.